Influence of docetaxel combined with cisplatin and single-agent cisplatin concurrent chemoradiotherapy in prognosis of patients with advanced cervical cancer and evaluation on security
10.13481/j.1671-587x.20170527
- VernacularTitle:紫杉醇联合顺铂与单药顺铂2种同步放化疗方案对中晚期宫颈癌患者预后的影响及安全性评价
- Author:
Simin WEN
1
;
Duo YU
;
Xin LYU
;
Tiejun WANG
Author Information
1. 吉林大学第一医院临床研究部
- Keywords:
docetaxel;
cisplatin;
cervical neoplasms;
prognostic factors;
security
- From:
Journal of Jilin University(Medicine Edition)
2017;43(5):1002-1008
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the influencing factors of prognosis in the patients with advanced cervical cancer,and to evaluate the influence of single-agent cisplatin and docetaxel combined with cisplatin concurrent chemoradiotherapy in the prognosis of the patients and the security,and to provide the basis for clinical treatment of advanced cervical cancer.Methods:A total of 218 patients with advanced cervical cancer who received the singleagent cisplatin or docetaxel combined with cisplatin concurrent chemoradiotherapy were enrolled as the subjects.The patients were divided into two groups according to their chemoradiotherapy treatments:single-agent group and docetaxel combined with cisplatin concurrent group.All the patients had received external beam radiation therapy combined with high-dose rate intracavitary hrachytherapy.A follow-up in 218 patients was performed until January 2017.The information about clinical characteristics including age,tumor diameter,clinical stage,chemotherapy treatments,pathological grade,pathological type,primiparous age and adverse effects after treatment were collected by telephone follow-up,outpatient service and reexamination.The differences in the clinical characteristics of the patients were compared between two groups,the association between the clinicopathological characteristics and the prognosis of the patients was analyzed,and the security of these two treatments was evaluated.Results:There were no statistical differences in the age,tumor diameter,clinical stage,pathological grade,pathological type and primiparous age of the patients between two groups (P＞0.05).The 1-year,3-year and 5-year overall survival (OS) rates of 218 patients were 96.33％,76.15％ and 63.76％,respectively.The 5-year OS rate of the patients in docetaxel combined with cisplatin group was higher than that of the patients in single-agent cisplatin group (x2 =8.032,P=0.005).The univariate analysis results indicated that tumor diameter,clinical stage,chemotherapy treatments,and adenocarcinoma were the potential predictive factors (P＜0.05).The Cox regression analysis results showed that clinical stage [stage Ⅲ:P=0.016,HR (95％CI) =1.90 (1.13-3.19) [stage Ⅳ:P＜ 0.001,HR (95％CI) =19.13 (7.84-46.68)],chemotherapy treatments [P=0.009,HR (95 ％CI) =0.54 (0.34-0.86)] and adenocarcinoma pathological type [P=0.021,HR (95％CI) =1.88 (1.10-3.21)] were the prognostic risk factors of the patients,the patients in clinical stage Ⅱ B,received docetaxel combined with cisplatin concurrent chemoradiotherapy and with pathological types of squamous cell carcinomas had a better outcome.Compared with docetaxel combined with cisplatin group,leucopenia (Z=-2.060,P =0.039) and neutropenia (Z=-2.246,P =0.025) in single-agent cisplatin group were lighter.Conclusion:Clinical stage,chemotherapy treatments and adenocarcinoma were the independently prognostic factors of the patients with advanced cervical cancer.The patients receive docetaxel combined with cisplatin concurrent chemoradiotherapy have a better prognosis and no severer adverse effects compared with single-agent cisplatin treatment.
